EL-02 · Péptido de investigación
Retatrutide
Opiniones de clientes
Aún no hay opiniones. Sé el primero en compartir tu experiencia.
EL-02 · Péptido de investigación
Aún no hay opiniones. Sé el primero en compartir tu experiencia.
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfechos
99,41 %
Prom. pureza 2026
4,8 ★
Valoración de la tienda
EL-02 · Reference data
GLP-1 / GIP / Glucagon Triagonist
Aliases: LY3437943
Research Use Only (RUO)
Research Use Only
Solo para uso en investigación (RUO). No destinado al consumo humano.
Retatrutide (research code LY3437943) is a cutting-edge research peptide and a novel next-generation triple agonist. It is the first molecule of its class to highly selectively and simultaneously bind to three crucial metabolic receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide), the GLP-1 receptor (glucagon-like peptide-1), and the Glucagon receptor (GCG-R).This unique triple mechanism of action sets Retatrutide fundamentally apart from previous dual agonists like Tirzepatide or mono-agonists like Semaglutide. While GIP and GLP-1 primarily modulate insulin secretion and control satiety via the central nervous system, the additional activation of the glucagon receptor opens up an entirely new metabolic pathway. This pathway directly targets the increase of basal energy expenditure and promotes hepatic lipid oxidation (fat burning in the liver). This synergistic effect makes Retatrutide one of the most promising and intensely studied peptides in global metabolic research.
The scientific and clinical relevance of Retatrutide is supported, among other data, by the highly acclaimed Phase 2 study by Jastreboff et al., published in 2023 in the prestigiousNew England Journal of Medicine(NEJM) (PubMed ID: 37385275). In this randomized, double-blind, and placebo-controlled trial, the peptide demonstrated unprecedented results over a 48-week period:
At Bergdorf Bioscience, Retatrutide is supplied as a high-purity, lyophilized (freeze-dried) powder. This complex manufacturing process extracts moisture from the peptide, ensuring maximum chemical stability and an exceptionally long shelf life, even at room temperature.
When you buy Retatrutide for your laboratory, you need absolute reliability. To guarantee maximum flexibility for a wide variety of research protocols and dose-finding studies, Retatrutide is available at Bergdorf Bioscience in five precisely graduated dosages:
Each vial is filled under the strictest laboratory conditions and individually sealed. All batches are analyzed using High-Performance Liquid Chromatography (HPLC) and feature a guaranteed purity of at least 99%. Our uncompromising quality assurance also includes detailed mass spectrometry to confirm the exact molecular weight, as well as rigorous endotoxin testing.
We offer reliableworldwide shipping for all our research peptides. Thanks to professional lyophilization, the Retatrutide powder is highly temperature-stable in its unmixed state. The molecular integrity and high biological activity of the peptide are fully preserved at normal ambient temperatures throughout the global transit. However, after reconstitution (mixing with bacteriostatic water), we highly recommend proper storage in a refrigerator.
Cada lote es analizado por un laboratorio independiente mediante HPLC antes del envío. Documentamos pureza (prom. 99,41 % en 2026), identidad por espectrometría de masas y esterilidad. La producción sigue estándares BPF en laboratorios con certificación ISO.
Ja, bei Eurolabs-Peptides als Referenzsubstanz für die Forschung (Materialbasis Eurolabs-Peptides). Verfügbare Dosierungen: 10, 15, 20, 30 und 50 mg pro Vial mit HPLC-verifizierter Reinheit von mindestens 99 Prozent.
Eli Lilly führt die Phase-3-Studien (TRIUMPH-Programm) bis 2026. Eine Marktzulassung als Arzneimittel in der EU wird frühestens 2027 erwartet. Als Referenzsubstanz ist Retatrutid bereits heute verfügbar.
Ab 112,99 Euro für 10 mg. Die 50-mg-Variante kostet 889,99 Euro und reduziert den Preis pro Milligramm deutlich. EU-Versand ab 250 Euro Bestellwert kostenfrei.
In der EU ist Retatrutid noch nicht als Arzneimittel zugelassen und damit auch nicht klassisch verschreibungspflichtig. Der Verkauf erfolgt ausschließlich als Referenzsubstanz für Laborforschung, nicht zur Anwendung am Menschen.
Tirzepatid (Mounjaro) ist ein Dual-Agonist an GIP- und GLP-1-Rezeptoren. Retatrutid ist ein Triple-Agonist und wirkt zusätzlich am Glucagon-Rezeptor. In Phase-2-Daten erreichte Retatrutid eine um circa 9 Prozentpunkte höhere Gewichtsreduktion.
Etwa 6 Tage (rund 144 Stunden), was eine wöchentliche Dosierung in Studien ermöglicht. Quelle: Eli Lilly Phase-2-Daten.
Retatrutid (Code LY3437943) wird von Eli Lilly and Company entwickelt, derzeit in Phase-3-Studien des TRIUMPH-Programms.
0,9 % alcohol bencílico
14,99 €